RxDoctor Payments Data

John Williams, MD

Internal Medicine · Green Bay, WINPI 1295717668

Payments from drug & device makers

$1,066in general payments, 2019–2025

Across 9 payments — averaging $118.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$255
  • AbbVie$125
  • Esperion Therapeutics, Inc.$125
  • AstraZeneca$125
  • Boehringer Ingelheim$125
  • Johnson & Johnson$120
  • plus $191 from 2 others

What the payments were for

  • Food & beverage$1,066100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,066 in reported general payments places this provider in the 85th percentile of 1,411 internal medicine providers in Wisconsin.

See all internal medicine providers in Wisconsin

Medicare billing

Part B allowed, 2024
$42,041
Medicare patients
183
Services billed
846

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban56$63,286
JanuviaSitagliptin Phosphate29$33,338
XareltoRivaroxaban26$29,028
JardianceEmpagliflozin22$24,378
SymbicortBudesonide/Formoterol Fumarate26$11,306
MyrbetriqMirabegron17$7,392
Atorvastatin Calcium600$6,280
Levothyroxine Sodium519$6,010
Losartan Potassium352$5,084
Omeprazole331$4,825
Potassium Chloride173$4,379
Fluticasone-SalmeterolFluticasone Propion/Salmeterol16$4,196
Gabapentin210$3,957
Albuterol Sulfate HfaAlbuterol Sulfate114$3,904
Metoprolol Succinate254$3,588

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$120$29,02826 claims
Boehringer IngelheimJardiance$125$24,37822 claims
AstraZenecaSymbicort$125$11,30626 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,411 internal medicine providers in Wisconsin.

Other internal medicine in Green Bay

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →